Drug Trial Radar · NCT07229729
A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Dec 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Nov 24, 2025
Primary completion
Oct 2026
Study completion Oct 2029
Sponsor
- Lead sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is a Phase II study to explore the efficacy and safety of SHR-A2102 in combination with other anti-tumor therapies as perioperative treatment in patients with resectable non-small cell lung cancer.
Conditions
- Non-small Cell Lung Cancer
Interventions
SHR-A2102Drug
SHR-A2102.
AdebrelimabDrug
Adebrelimab.
PaclitaxelDrug
Paclitaxel.
CarboplatinDrug
Carboplatin.
Alomnertinib MesilateDrug
Alomnertinib Mesilate.
Furmonertini MesilateDrug
Furmonertini Mesilate.
Osimertinib MesylateDrug
Osimertinib Mesylate.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pathology complete response (pCR)Time frame: Up to approximately 20 weeks.
- 18-month event free rateTime frame: Up to approximately 18 months.
- 2-years disease free rateTime frame: Up to approximately 2 years.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.